Furthermore, increased PODXL expression has been associated with high-grade tumors and poor clinical outcome in breast cancer [22], colorectal cancer [23,40,42,54], pancreatic ductal adenocarcinoma [35], ovarian cancer [25], renal cell carcinoma [26], urothelial bladder cancer [44,55], glioblastoma multiforme [45], gastric cancer [49,50,51,52], uterine endometrioid adenocarcinoma [43], periampullary adenocarcinoma [56], and esophageal adenocarcinoma [50]. This evidence concerns the gene PODXL and breast cancer.